MARKET

CNCR

CNCR

Loncar Cancer Immunotherapy ETF
NASDAQ

Real-time Quotes | Provided by Morningstar

21.93
-0.13
-0.59%
Opening 13:49 01/29 EST
OPEN
22.07
PREV CLOSE
22.06
HIGH
22.07
LOW
21.93
VOLUME
3.83K
TURNOVER
--
52 WEEK HIGH
24.57
52 WEEK LOW
17.82
TOTAL ASSET
36.54M
YTD YIELD
-6.23%
1D
5D
1M
3M
1Y
5Y

Tools for In-Depth Analysis of CNCR, Buy or Sell Stocks and ETFs Commission-Free!

Open a Webull account and fund it to get a free stock

CNCR News

  • Investing In The Holy Grail Of Cancer Treatment: Immunotherapy
  • Seeking Alpha - Article.11/22/2019 18:34
  • VXX, UNG, UGAZ and TVIX among weekly ETF movers
  • Seeking Alpha - Article.11/01/2019 20:54
  • Aprea Therapeutics upsizes IPO amid turbulent biotech market
  • Seeking Alpha - Article.10/03/2019 14:09
  • Health Care Sector Innovation And Insight
  • Seeking Alpha - Article.08/14/2019 10:23

More

Profile

Fund Name
Loncar Cancer Immunotherapy ETF
Risk
High Risk
Inception Date
2015-10-13
Benchmark
Loncar Cancer Immunotherapy TR USD*100.0%
Advisor Company
Loncar Investments
Custodian
U.S. Bank N.A
Manager
Denise Krisko, Austin Wen

Asset Allocation

39.92M
  • 99.9403%
  • 0.00%
  • 0.0597%
  • 0.00%

2019 Q4

39.92M

2019 Q2

38.09M

2019 Q1

38.87M

2018 Q4

38.54M

2018 Q3

55.70M

Dividend History

Ex-Div Date
Dividend Per Share
12/28/2017
0.3502
12/29/2015
0.1055